DRAs for Neurogenic Detrusor Overactivity: A Systematic Review

What is it about?

This study evaluates the therapeutic benefits and safety of oral detrusor relaxing agents (DRAs) in treating neurogenic detrusor overactivity (NDO). A systematic review and meta-analysis of 23 randomized controlled trials (RCTs) involving 1697 patients found that oral DRAs led to improved outcomes compared to placebo, along with more adverse events. Antimuscarinics were more effective in improving urodynamic and bladder diary outcomes, with a higher rate of xerostomia as a side effect. Mirabegron improved some parameters and had fewer bothersome side-effects. The study found no significant difference in efficacy and safety between antimuscarinics and mirabegron for NDO. While antimuscarinics remain the first-line treatment, the role of mirabegron is still unclear and more research is needed.

Featured Image

Why is it important?

This research is important because it provides evidence regarding the therapeutic benefits and safety of oral detrusor relaxing agents (DRAs) in treating neurogenic detrusor overactivity (NDO). The study helps healthcare professionals make informed decisions about the best treatment options for patients with NDO. Key Takeaways: 1. Oral DRAs, along with more adverse events (AEs), are associated with improved outcomes in patients with NDO. 2. Antimuscarinics significantly improve both urodynamic and bladder diary outcomes, including urinary incontinence episodes, urinary frequency, and residual volume, with a higher rate of AEs, such as xerostomia. 3. Mirabegron improved some of the parameters and had fewer bothersome side-effects in patients with NDO. 4. None of the antimuscarinics or mirabegron was superior or inferior to the other. 5. Evidence concerning mirabegron as first-line therapy for NDO is still limited. 6. Further well-designed randomized controlled trials (RCTs) are required in this specific population.